Remus Pharmaceuticals IPO will open for subscription from 17 May 2023. the company aims for an issue size of ₹47.69 Cr through this IPO.
About Company
Incorporated in 2015, Remus Pharmaceuticals is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. It also deals in API (Active Pharmaceutical Ingredient). The company also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries.
The company has cultivated strong and dependable customer relationships ranging from generic distributors, regional distributors, and multinational distributors to Hospitals and Clinics through a responsive distribution network. Remus’ clients are spread in more than 20 countries and its product portfolio consisted of 429 products, as on 31 January 2023. Remus Pharmaceuticals deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.
Basic details about the company
| Full name | Remus Pharmaceuticals Limited |
| Sector | Trading |
| Industry | Trading |
| Company Website | https://remuspharma.com/ |
The Objective of the Issue
- To Meet Working Capital Requirements,
- Funding investments for acquisitions and general corporate purposes,
- To meet Public Issue Expenses.
IPO Timetable
| IPO Opening date | 17 May 2023 |
| IPO Closing | 19 May 2023 |
| Basis of Allotment | 24 May 2023 |
| Initiation Refund | 25 May 2023 |
| Credit to Demat Account | 26 May 2023 |
| Listing Date | 29 May 2023 |
IPO details
| Issue type | Book Built Issue IPO |
| IPO issue size | ₹47.69 Cr – 388,000 shares |
| Fresh Issue | ₹47.69 Cr – 388,000 shares |
| Offer for sale | Nil |
| Face value | ₹10 per share |
| Price Band | ₹1150 to ₹1229 per share |
| Lot size | 100 Shares |
| Retail Allocation | 25.03% |
| Listing Exchange | NSE SME |
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 100 | ₹122,900 |
| Retail (Max) | 1 | 100 | ₹122,900 |
| HNI (Min) | 2 | 200 | ₹245,800 |
Reservation Details
| QIB Shares Offered | 138,750 Shares (35.76%) |
| NII (HNI) Shares Offered | 41,625 Shares (10.73%) |
| Retail Shares Offered | 97,125 Shares (25.03%) |
| Anchor Investor Shares Offered | 110,500 Shares (28.48%) |
| Market Maker portion | 19,500 shares |
Financial Performance
| FY 2020 | FY 2021 | FY 2022 | 9M FY 2023 | |
| Revenue | 11.92 | 18.42 | 24.72 | 32.39 |
| Expenses | 11.67 | 17.87 | 20.89 | 24.92 |
| Net income | 0.81 | 1.03 | 3.39 | 6.44 |
Valuations & Margins
| FY 2020 | FY 2021 | FY 2022 | |
| EPS | 8.12 | 10.26 | 33.86 |
| PE ratio | – | – | 33.96 – 36.30 |
| RONW (%) | 40.17 | 33.68 | 52.64 |
| NAV | – | – | 64.32 |
| ROCE (%) | 47.76 | 41.90 | 69.99 |
| EBITDA (%) | 10.42 | 8.51 | 19.38 |
| Debt/Equity | 0.18 | 0.09 | 0.03 |
Company Promoters
- Mr. Arpit Deepakkumar Shah
- Ms. Roma Vinodbhai Shah
- Mr. Swapnil Jatinbhai Shah
- Mrs. Anar Swapnil Shah
Promoter Holding
| Pre Issue Share Holding | 92.82% |
| Post Issue Share Holding | 68.37% |
Lead Manager(s)
BEELINE CAPITAL ADVISORS PRIVATE LIMITED
807, Phoenix, Opp. Girish Cold Drinks,
Near Vijay Cross Roads, Navrangpura, Ahmedabad -380009
Phone: 079 4840 5357
Email: mb@beelinemb.com
Website: www.beelinemb.com
IPO Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park,
Lal Bahadur Shastri Marg, Vikhroli (West),
Mumbai, Maharashtra, India – 400 083
Phone: +91 810 811 4949
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: www.linkintime.co.in
Contact Details
REMUS PHARMACEUTICALS LIMITED
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad – 380054, Gujarat
Phone: +079- 2999 9857
E-mail: cs@remuspharma.com
Website: www.remuspharma.com
Allotment Status
Remus Pharmaceuticals IPO allotment status will be available on Link Intime’s website. Click on Link Intime IPO weblink to get allotment status.
Final thoughts
Remus Pharmaceuticals IPO is going to hit Dalal Street soon. applying for an IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make wise decisions.
Happy Investing
